Breakthrough Therapies for Metastatic & Primary Cancers

Our multi-patented, ZetaMet™ (Zeta-BC-003) therapy is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone with the potential to increase survival rates.

Latest Updates

Publications & Press Releases

Empire State Development Announces More Than $4M Awarded to Small Businesses Through NYSTAR’s Innovation Matching Grants Program

Friday, November 15, 2024 – Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) today announced that 35 businesses have been awarded $4,637,226.00 in Round 1 & 2 of its new Innovation Matching Grants program.

Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer

November 12, 2024, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic breast cancer to bone and soft tissues, announced today that the first two patients have enrolled in the phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).

New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse® as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer Patients

September 24, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs, today announced publication of clinical data in the peer-reviewed Journal of the American Academy of Orthopaedic Surgeons (JAAOS) on ZetaFuse® (Zeta-ZF-002) for the treatment of multi-level DDD in a Stage 4 lung cancer patient.
What we do
For Our
Patients
Zetagen is focused on the 330,000 people in the United States and more globally, annually living with some form of bone metastases. We have created a series of novel therapies which address metastatic cancers at progressive stages. Our therapies are designed to suspend cancer, inhibit pain, and regenerate bone with the potential of increasing survival rates. These novel drugs from Zetagen are adjunctive to other cancer treatments and can be locally administered, to bone or soft tissue organs, when the lesion is first detected via a brief out-patient procedure. Pre-clinical studies and peer-review published data have shown the potential to reduce lesion size by 200% and in some cases completely resolve, reduce pain by 400+%, and improve mortality rates of 250%.
Discover More
0
k
Patients Annually Diagnosed with Breast Cancer
(1 out of 8 Women)
0
k
Patients Annually Diagnosed with Metastatic Lytic Bone Lesions
(Breast, Lung, Myeloma, and Prostate)
0
%
% of patients Develop Skeletal-Related Event (SRE) from Metastatic Lytic Bone Lesions
*References: Australia (nbcf.org.au) | Canada (cancer.ca) | USA (breastcancer.org, ncbi.nlm.nih.gov, sciencedirect.com)
Breakthrough Technology

For Metastatic Therapies

The U.S Food and Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Designations. Zetagen discovered and patented the first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. The small molecule has been approved by the FDA since 1971. Our research scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.
Learn More